# Discover companies before major catalysts Canonical URL: https://biopharmsignal.com/use-cases/small-biotech-fund-teams/discover-companies-before-major-catalysts Role: [Small Biotech Fund Teams](https://biopharmsignal.com/use-cases/small-biotech-fund-teams.md) Category: Catalysts and competitive evidence Last updated: 2026-07-26 Turn industry events into a disciplined research candidate queue. ## The Situation The fund wants to find research candidates early enough to complete diligence before a clinical, regulatory, or conference catalyst becomes crowded. ### Best Fit Portfolio managers, analysts, associates, and operations leads at small healthcare and event-driven investment funds. ## The Challenge Turn industry events into a disciplined research candidate queue. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information. ## How To Think About The Task The fund wants to find research candidates early enough to complete diligence before a clinical, regulatory, or conference catalyst becomes crowded. For small fund teams, the useful response is not simply to collect more links. The task is to decide what the new information changes, which source supports it, who needs to respond, and when the question should be reviewed again. Turn industry events into a disciplined research candidate queue. The challenge is to preserve the source, define what changed, and connect the update to a decision instead of collecting disconnected information. A repeatable process keeps the work proportional to the decision and creates a record that another investor, analyst, editor, or team member can understand later. ### Start with the decision this work must support “Discover companies before major catalysts” becomes manageable when the user names the decision before opening more sources. The decision might be whether to escalate an event, update a thesis, change a calendar, commission deeper research, publish a story, or continue monitoring. A defined decision also makes it easier to exclude information that is interesting but not currently useful. ### Build a source-linked change record The core monitoring set for this workflow includes future catalyst windows, evidence available before the event, cash and financing position, competitive landscape, research time required. Each material update should retain its source and previous known state. That makes timing changes, accumulating evidence, and repeated execution patterns visible instead of leaving the user with an isolated snapshot. ### Turn monitoring into an owned output A catalyst-driven research queue ranked by informational value, timing confidence, evidence quality, financing risk, and required diligence. The output should state what changed, what remains uncertain, who owns any follow-up, and which future event will resolve the question. The team allocates research time before the event rather than discovering the company after attention and volatility have already increased. ## Illustrative Example ### Illustrative workflow: discover companies before major catalysts Begin with the specific company, program, portfolio exposure, audience, or competitive set in scope. Review the highest-confidence source first, compare the disclosure with the previous record, and then use secondary context only where it helps explain the change. Complete the workflow by producing the defined deliverable rather than ending with a collection of tabs. Assign any unresolved question to an owner and set the next review around the most relevant clinical, regulatory, financial, strategic, or editorial event. ### Questions To Answer Before Making A Decision - What has changed in future catalyst windows, and why does it matter? - What has changed in evidence available before the event, and why does it matter? - What has changed in cash and financing position, and why does it matter? - What has changed in competitive landscape, and why does it matter? - What has changed in research time required, and why does it matter? ## A Repeatable Workflow 1. Define the specific decision or research question behind “discover companies before major catalysts.” 2. Set the monitored scope around future catalyst windows and evidence available before the event. 3. Collect source-linked updates for cash and financing position and record what changed from the prior state. 4. Review competitive landscape together with research time required before drawing a conclusion. 5. Produce the required output, assign follow-up ownership, and set the next review point. ## Signals To Keep Visible - Future catalyst windows - Evidence available before the event - Cash and financing position - Competitive landscape - Research time required ## Common Mistakes - Starting the monitoring process without a defined decision question - Recording the latest state without preserving its source or previous state - Ending with collected information but no owner, conclusion, or next review ## Deliverable A catalyst-driven research queue ranked by informational value, timing confidence, evidence quality, financing risk, and required diligence. ## Practical Outcome The team allocates research time before the event rather than discovering the company after attention and volatility have already increased. ## Where BioPharmSignal Fits Use LiveFeed and company pages for source-linked monitoring, the PDUFA Calendar for upcoming FDA milestones, and watchlists or alerts to keep relevant tickers and keywords visible. The workflow still requires independent research and judgment. ## Frequently Asked Questions ### Who is this workflow for? It is designed for small biotech fund teams and adjacent biotech research users who need a repeatable, source-linked way to complete this task. ### What should this workflow produce? A catalyst-driven research queue ranked by informational value, timing confidence, evidence quality, financing risk, and required diligence. ### What is the practical benefit? The team allocates research time before the event rather than discovering the company after attention and volatility have already increased. ## Related Workflows - [How a Small Biotech Fund Builds a Daily News Briefing](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/daily-biotech-news-briefing.md) - [How Small Funds Maintain a Shared Biotech Catalyst Calendar](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/shared-biotech-catalyst-calendar.md) - [How Small Funds Track Competitive Read-Throughs in Biotech](https://biopharmsignal.com/use-cases/small-biotech-fund-teams/competitive-read-throughs.md) Format note: This is an illustrative workflow guide, not a named customer testimonial or a claim of investment performance.